Showing results (1-10 of 274) with videos related to
Sort By:
Pageof 28
Cancer Cell|January 1, 2026
Adaptive plasticity in targeted therapyVito Amodio, Giorgio Patelli, Alberto BardelliCell|April 17, 2026
SnapShot: The hallmarks of cancer treatmentPietro Paolo Vitiello, Vito Amodio, Alberto BardelliCancer Discovery|September 4, 2025
Detecting Cancer Early with Ultrasensitive Multimodal Liquid BiopsyGiovanni Crisafulli, Nadia Saoudi Gonzalez, Giorgio Patelli, et al.Cell|February 7, 2025
Tumor "age" in early-onset colorectal cancerGianluca Mauri, Giorgio Patelli, Giovanni Crisafulli, et al.Cancer Research|September 24, 2025
Mismatch Repair as a Dynamic and Clinically Actionable Vulnerability in CancerEleonora Piumatti, Pietro Paolo Vitiello, Vito Amodio, et al.Cancers|June 2, 2021
Mechanisms of Immune Escape and Resistance to Checkpoint Inhibitor Therapies in Mismatch Repair Deficient Metastatic Colorectal CancersVito Amodio, Gianluca Mauri, Nicole M Reilly, et al.Cell Reports. Medicine|September 11, 2024
Early-onset cancers: Biological bases and clinical implicationsGianluca Mauri, Giorgio Patelli, Andrea Sartore-Bianchi, et al.Cancer Treatment Reviews|October 22, 2020
Oxaliplatin retreatment in metastatic colorectal cancer: Systematic review and future research opportunitiesGianluca Mauri, Viviana Gori, Erica Bonazzina, et al.Frontiers in Oncology|November 24, 2022
Case Report: <i>MAP2K1 K57N</i> mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancerGianluca Mauri, Giorgio Patelli, Viviana Gori, et al.Frontiers in Oncology|April 14, 2023
Corrigendum: Case report: <i>MAP2K1 K57N</i> mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancerGianluca Mauri, Giorgio Patelli, Viviana Gori, et al.Pageof 28